Roth Capital Initiates Coverage On Kalera with Buy Rating, Announces Price Target of $6
Roth Capital analyst Brian White initiates coverage on Kalera (NASDAQ:KAL) with a Buy rating and announces Price Target of $6.
Raymond James Downgrades First Commonwealth to Market Perform
Raymond James analyst David Feaster downgrades First Commonwealth (NYSE:FCF) from Outperform to Market Perform.
Senate Finance Committee Probe Reveals How AbbVie Exploits Offshore Subsidiaries To Avoid Tax Bills
Provisions in the 2017 Republican tax law allow AbbVie Inc (NYSE: ABBV) to generate most of its sales in the U.S. while reporting virtually no income in the U.S. for tax purposes.
Raymond James Downgrades CapStar Finl Hldgs to Market Perform
Raymond James analyst William Wallace downgrades CapStar Finl Hldgs (NASDAQ:CSTR) from Outperform to Market Perform.
Keybanc Maintains Overweight on Welltower OP, Lowers Price Target to $95
Keybanc analyst Josh Beck maintains Welltower OP (NYSE:WELL) with a Overweight and lowers the price target from $98 to $95.
Citigroup Maintains Buy on Interpublic Gr of Cos, Lowers Price Target to $33
Citigroup analyst Jason Bazinet maintains Interpublic Gr of Cos (NYSE:IPG) with a Buy and lowers the price target from $43 to $33.
High Tide To Acquire Nine Operating Retail Cannabis Stores From Choom
High Tide Inc. (NASDAQ: HITI) (TSXV:HITI) (FSE:2LYA) is further expanding its bricks-and-mortar retail cannabis operations and entering the British Columbia market, through a binding agreement pursuant to which High Tide will acquire two operating retail cannabis st
Keybanc Maintains Overweight on Block, Lowers Price Target to $80
Keybanc analyst Josh Beck maintains Block (NYSE:SQ) with a Overweight and lowers the price target from $180 to $80.
Citigroup Maintains Buy on Genius Sports, Lowers Price Target to $6
Citigroup analyst Jason Bazinet maintains Genius Sports (NYSE:GENI) with a Buy and lowers the price target from $8 to $6.
iSpecimen Adds New Global Biospecimen Suppliers To Proprietary Marketplace Platform For Researchers To Leverage
iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare